Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs launches CellRapeutics™ allogeneic CAR-T cell development service, which achieves further enhancement of CAR-T cells by converting inhibitory molecular signals into activated signaled CAR-T cells.
Inhibitory signals in the tumor microenvironment can have a series of negative effects on the immune response against the tumor. One of the key effects is the suppression of immune cell activity, particularly of cytotoxic T cells that are responsible for killing tumor cells. Inhibitory signals can prevent these immune cells from recognizing and attacking the tumor, allowing it to continue growing unchecked. In addition, inhibitory signals can also promote the recruitment of immune cells that suppress the immune response, such as regulatory T cells and myeloid-derived suppressor cells. These cells can further dampen the immune response against the tumor, creating a vicious cycle of immunosuppression that allows the tumor to thrive.
Fig.1 Immune cells and immune checkpoints in the tumor microenvironment.1
After further research on CAR-T cells, Creative Biolabs has developed a set of enhanced CAR-T therapy strategies that target the tumor microenvironment and actively explore a highly differentiated pathway to further unlock the potential of tumor immunotherapy. Our CellRapeutics™ Allogeneic CAR-T Cell platform not only blocks endogenous TME molecular signaling, but also converts tumor microenvironment inhibitory signals into T cell activation signals, thereby promoting the expansion and persistence of CAR-T cells in tumor tissues.
Creative Biolabs designed chimeric receptors to have a signaling domain that activates CAR-T cells when bound to inhibitory molecules. This activation signal can then override the inhibitory signal, leading to the activation of CAR-T cells and subsequent killing of target cancer cells. Another approach is to use genetic engineering techniques to modify CAR-T cells so that they can overcome inhibitory signals. For example, CAR-T cells can be designed to express molecules that can inhibit inhibitory receptor activity, or express additional costimulatory molecules that can enhance CAR-T cell activation.
Enhance T cell expansion capacity
Prolongs T cell fitness and persistence
Improve the ability to fight against the tumor microenvironment
Improve the ability to kill tumors with large loads
Enhance immune memory
CellRapeutics™ Allogeneic CAR-T Cell Development Service offers cutting-edge solutions for the development of allogeneic CAR-T cell therapies. Our team of experts is dedicated to advancing the field of CAR-T cell therapy and providing our clients with high-quality, customizable solutions for their specific needs. With a strong focus on innovation and collaboration, we are committed to delivering results that have the potential to revolutionize the treatment of cancer and other diseases.
All in all, Creative Biolabs is your best partner in advancing the field of CAR-T cell therapy. With our expertise and state-of-the-art technology, we are equipped to help you bring your therapies from concept to clinic. Contact us now to learn more about how we can help you achieve your goals in cell therapy development.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
